Search | Virtual Health Library

1.

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.

Buchan, Sarah L; Dou, Lang; Remer, Marcus; Booth, Steven G; Dunn, Stuart N; Lai, Chester; Semmrich, Monika; Teige, Ingrid; Mårtensson, Linda; Penfold, Christine A; Chan, H T Claude; Willoughby, Jane E; Mockridge, C Ian; Dahal, Lekh N; Cleary, Kirstie L S; James, Sonya; Rogel, Anne; Kannisto, Päivi; Jernetz, Mats; Williams, Emily L; Healy, Eugene; Verbeek, J Sjef; Johnson, Peter W M; Frendéus, Björn; Cragg, Mark S; Glennie, Martin J; Gray, Juliet C; Al-Shamkhani, Aymen; Beers, Stephen A.

Immunity ; 49(5): 958-970.e7, 2018 11 20.

Article in English | MEDLINE | ID: mdl-30446386

2.

KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.

Blunt, Matthew D; Vallejo Pulido, Andres; Fisher, Jack G; Graham, Lara V; Doyle, Amber D P; Fulton, Rebecca; Carter, Matthew J; Polak, Marta; Johnson, Peter W M; Cragg, Mark S; Forconi, Francesco; Khakoo, Salim I.

J Immunol ; 209(2): 379-390, 2022 07 15.

Article in English | MEDLINE | ID: mdl-35768150

3.

Are we reaching the maximum cure rate for Hodgkin lymphoma?

Johnson, Peter W M.

Hematol Oncol ; 41 Suppl 1: 57-61, 2023 Jun.

Article in English | MEDLINE | ID: mdl-37294968

4.

Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.

Ahmed, Sophia; Glover, Paul; Taylor, Jan; Sha, Chulin; Care, Matthew A; Tooze, Reuben; Davies, Andrew; Westhead, David R; Johnson, Peter W M; Burton, Catherine; Barrans, Sharon L.

Br J Haematol ; 192(3): 599-604, 2021 02.

Article in English | MEDLINE | ID: mdl-33249557

5.

Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.

Longley, Jemma; Johnson, Peter W M.

Hematol Oncol ; 39 Suppl 1: 39-45, 2021 Jun.

Article in English | MEDLINE | ID: mdl-34105815

6.

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.

Longley, Jemma; Johnson, Peter W M.

Curr Oncol Rep ; 23(7): 76, 2021 05 03.

Article in English | MEDLINE | ID: mdl-33937922

7.

Optimizing therapy in advanced-stage Hodgkin lymphoma.

Lim, Sean H; Johnson, Peter W M.

Blood ; 131(15): 1679-1688, 2018 04 12.

Article in English | MEDLINE | ID: mdl-29500173

8.

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Davies, Andrew; Cummin, Thomas E; Barrans, Sharon; Maishman, Tom; Mamot, Christoph; Novak, Urban; Caddy, Josh; Stanton, Louise; Kazmi-Stokes, Shamim; McMillan, Andrew; Fields, Paul; Pocock, Christopher; Collins, Graham P; Stephens, Richard; Cucco, Francesco; Clipson, Alexandra; Sha, Chulin; Tooze, Reuben; Care, Matthew A; Griffiths, Gareth; Du, Ming-Qing; Westhead, David R; Burton, Catherine; Johnson, Peter W M.

Lancet Oncol ; 20(5): 649-662, 2019 05.

Article in English | MEDLINE | ID: mdl-30948276

9.

Current treatment paradigms for advanced stage Hodgkin lymphoma.

Longley, Jemma; Johnson, Peter W M.

Br J Haematol ; 184(1): 60-71, 2019 01.

Article in English | MEDLINE | ID: mdl-30408156

10.

Smart salvage treatment for Hodgkin lymphoma.

Johnson, Peter W M.

Blood ; 139(25): 3563-3564, 2022 06 23.

Article in English | MEDLINE | ID: mdl-35737409

11.

Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume.

Ceriani, Luca; Milan, Lisa; Johnson, Peter W M; Martelli, Maurizio; Presilla, Stefano; Giovanella, Luca; Zucca, Emanuele.

Eur J Nucl Med Mol Imaging ; 46(6): 1334-1344, 2019 Jun.

Article in English | MEDLINE | ID: mdl-30806751

12.

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.

Anderson, Richard A; Remedios, Rachel; Kirkwood, Amy A; Patrick, Pip; Stevens, Linsey; Clifton-Hadley, Laura; Roberts, Tom; Hatton, Chris; Kalakonda, Nagesh; Milligan, Don W; McKay, Pam; Rowntree, Clare; Scott, Fiona M; Johnson, Peter W M.

Lancet Oncol ; 19(10): 1328-1337, 2018 10.

Article in English | MEDLINE | ID: mdl-30220622

13.

Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.

Ceriani, Luca; Martelli, Maurizio; Conconi, Annarita; Zinzani, Pier L; Ferreri, Andrés J M; Botto, Barbara; Stelitano, Caterina; Gotti, Manuel; Cabras, Maria G; Rigacci, Luigi; Giovanella, Luca; Zucca, Emanuele; Johnson, Peter W M.

Br J Haematol ; 178(4): 588-591, 2017 08.

Article in English | MEDLINE | ID: mdl-28485042

14.

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.

Blunt, Matthew D; Carter, Matthew J; Larrayoz, Marta; Smith, Lindsay D; Aguilar-Hernandez, Maria; Cox, Kerry L; Tipton, Thomas; Reynolds, Mark; Murphy, Sarah; Lemm, Elizabeth; Dias, Samantha; Duncombe, Andrew; Strefford, Jonathan C; Johnson, Peter W M; Forconi, Francesco; Stevenson, Freda K; Packham, Graham; Cragg, Mark S; Steele, Andrew J.

Blood ; 125(26): 4032-41, 2015 Jun 25.

Article in English | MEDLINE | ID: mdl-25957390

15.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

Ceriani, Luca; Martelli, Maurizio; Zinzani, Pier Luigi; Ferreri, Andrés J M; Botto, Barbara; Stelitano, Caterina; Gotti, Manuel; Cabras, Maria Giuseppina; Rigacci, Luigi; Gargantini, Livio; Merli, Francesco; Pinotti, Graziella; Mannina, Donato; Luminari, Stefano; Stathis, Anastasios; Russo, Eleonora; Cavalli, Franco; Giovanella, Luca; Johnson, Peter W M; Zucca, Emanuele.

Blood ; 126(8): 950-6, 2015 Aug 20.

Article in English | MEDLINE | ID: mdl-26089397

16.

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.

Illidge, Tim M; McKenzie, Hayley S; Mayes, Sam; Bates, Andrew; Davies, Andrew J; Pettengell, Ruth; Stanton, Louise; Cozens, Kelly; Hampson, Grace; Dive, Caroline; Zivanovic, Maureen; Tipping, Jill; Gallop-Evans, Eve; Radford, John A; Johnson, Peter W M.

Br J Haematol ; 173(2): 274-82, 2016 Apr.

Article in English | MEDLINE | ID: mdl-26849853

17.

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.

Gleeson, Mary; Hawkes, Eliza A; Cunningham, David; Chadwick, Nick; Counsell, Nicholas; Lawrie, Anthony; Jack, Andrew; Smith, Paul; Mouncey, Paul; Pocock, Christopher; Ardeshna, Kirit M; Radford, John; McMillan, Andrew; Davies, John; Turner, Deborah; Kruger, Anton; Johnson, Peter W M; Gambell, Joanna; Linch, David.

Br J Haematol ; 175(4): 668-672, 2016 Nov.

Article in English | MEDLINE | ID: mdl-27477167

18.

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.

Rule, Simon; Smith, Paul; Johnson, Peter W M; Bolam, Simon; Follows, George; Gambell, Joanne; Hillmen, Peter; Jack, Andrew; Johnson, Stephen; Kirkwood, Amy A; Kruger, Anton; Pocock, Christopher; Seymour, John F; Toncheva, Milena; Walewski, Jan; Linch, David.

Haematologica ; 101(2): 235-40, 2016 Feb.

Article in English | MEDLINE | ID: mdl-26611473

19.

Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization.

Willoughby, Jane E; Kerr, Jonathan P; Rogel, Anne; Taraban, Vadim Y; Buchan, Sarah L; Johnson, Peter W M; Al-Shamkhani, Aymen.

J Immunol ; 193(1): 244-51, 2014 Jul 01.

Article in English | MEDLINE | ID: mdl-24860188

20.

FcÎ³ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.

White, Ann L; Dou, Lang; Chan, H T Claude; Field, Vikki L; Mockridge, C Ian; Moss, Kane; Williams, Emily L; Booth, Steven G; French, Ruth R; Potter, Elizabeth A; Butts, Cherié; Al-Shamkhani, Aymen; Cragg, Mark S; Verbeek, J Sjef; Johnson, Peter W M; Glennie, Martin J; Beers, Stephen A.

J Immunol ; 193(4): 1828-35, 2014 Aug 15.

Article in English | MEDLINE | ID: mdl-25024386

Virtual Health Library

United States - Mexico Border

Your selection (0)

Export format:

Export:

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.

KIR2DS2 Expression Identifies NK Cells With Enhanced Anticancer Activity.

Are we reaching the maximum cure rate for Hodgkin lymphoma?

Comparative analysis of gene expression platforms for cell-of-origin classification of diffuse large B-cell lymphoma shows high concordance.

Personalized medicine for Hodgkin lymphoma: Mitigating toxicity while preserving cure.

Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.

Optimizing therapy in advanced-stage Hodgkin lymphoma.

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.

Current treatment paradigms for advanced stage Hodgkin lymphoma.

Smart salvage treatment for Hodgkin lymphoma.

Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume.

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.

Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial.

Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization.

FcÎ³ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.